Two Sigma Securities’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Two Sigma Securities’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,115	Closed	-$232	–	1535
2025 Q2	$232	Sell	13,115 -100	-0.8%	-$2	﹤0.01%	1432
2025 Q1	$231	Buy	13,215 +358	+3%	+$8	﹤0.01%	1384
2024 Q4	$138	Buy	+12,857	New	+$135	﹤0.01%	1539

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Securities's DRMAW Position: Q3 2025 in Review

Two Sigma Securities sold out of Dermata Therapeutics Warrant (DRMAW) in Q3 2025, closing a stake of 13,115 shares — an estimated $232 sold.

Two Sigma Securities first reported a position in DRMAW in Q4 2024 and held it in 3 quarters. The position peaked at $232 in Q2 2025. 3 funds tracked by Wall St. Rank hold DRMAW as of Q3 2025.

Two Sigma Securities reported no remaining Dermata Therapeutics Warrant position as of Q3 2025 after selling out during the quarter.
Two Sigma Securities sold 13,115 Dermata Therapeutics Warrant shares in Q3 2025, an estimated $232.
Two Sigma Securities first reported a position in Dermata Therapeutics Warrant in Q4 2024 and held it in 3 quarters.
Two Sigma Securities's Dermata Therapeutics Warrant position peaked at $232 in Q2 2025.
3 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.